The UGT1A1*28 genotype and the toxicity of low-dose irinotecan in patients with advanced lung cancer

Oncology Research

Volumn 18, Issue 7, 2010, Pages 337-342

  Sugiyama, Tomohide ^a   Hirose, Takashi ^a   Kusumoto, Sojiro ^a   Shirai, Takao ^a   Yamaoka, Toshimitsu ^a   Okuda, Kentaro ^a   Ohnishi, Tsukasa ^a   Ohmori, Tohru ^a   Adachi, Mitsuru ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Low dose irinotecan; Lung cancer; Toxicity; UGT1A1*28 genotype

Indexed keywords

CARBOPLATIN; CISPLATIN; DEXAMETHASONE; DOCETAXEL; GENOMIC DNA; GLUCURONOSYLTRANSFERASE 1A1; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; LOPERAMIDE; ONDANSETRON; ANTINEOPLASTIC AGENT; BILIRUBIN URIDINE DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; BILIRUBIN URIDINE-DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; CAMPTOTHECIN; DRUG DERIVATIVE; GLUCURONOSYLTRANSFERASE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD CELL COUNT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; JAPANESE; LEUKOCYTE COUNT; LEUKOPENIA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE; WILD TYPE; GENETIC POLYMORPHISM; GENETICS; HETEROZYGOTE; HOMOZYGOTE; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; GLUCURONOSYLTRANSFERASE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; RETROSPECTIVE STUDIES; SMALL CELL LUNG CARCINOMA;

EID: 77950588150     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504010X12626118079822     Document Type: Article

References (21)

1. Kunimoto, T.; Nitta, K.; Tanaka, T.; Uehara, N.; Baba, H.; Takeuchi, M.; Yokokura, T.; Sawada, S.; Miyasaka, T.; Mutai, M. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res. 47:5944-5947; 1987.
2. de Forni, M.; Bugat, R.; Chabot, G. G.; Culine, S.; Extra, J. M.; Gouyette, A.; Madelaine, I.; Marty, M. E.; Mathieu-Boue, A. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on weekly schedule in cancer patients. Cancer Res. 54:4347-4354; 1994.
3. Slatter, J. G.; Su, P.; Sams, J. P.; Schaaf, L. J.; Wienkers, L. C. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab. Dispos. 25:1157-1164; 1997.
4. Iyer, L.; King, C. D.; Whitington, P. F.; Green, M. D.; Roy, S. K.; Tephly, T. R.; Coffman, B. L.; Ratain, M. J. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J. Clin. Invest. 15:847-854; 1998.
5. Kawato, Y.; Aonuma, M.; Hirota, Y.; Kuga, H.; Sato, K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect or CPT-11. Cancer Res. 51:4187-4191; 1991.
6. Ando, Y.; Saka, H.; Ando, M.; Sawa, T.; Muro, K.; Ueoka, H.; Yokoyama, A.; Saitoh, S.; Shimokata, K.; Hasegawa, Y. Polymorphisms of UDP- glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis. Cancer Res. 60:6921-6926; 2000. (Pubitemid 32059164)
7. Massacesi, C.; Terrazzino, S.; Marcucci, F.; Rocchi, M. B.; Lippe, P.; Bisonni, R.; Lombardo, M.; Pilone, A.; Mattioli, R.; Leon, A. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer 106:1007-1016; 2006. (Pubitemid 43297338)
8. Innocenti, F.; Undevia, S. D.; Iyer, L.; Chen, P. X.; Das, S.; Kocherginsky, M.; Karrison, T.; Janisch, L.; Ramirez, J.; Rudin, C. M.; Vokes, E. E.; Ratain, M. J. Genetic variants in the UDP- glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 22:1382-1388; 2004.
9. Marcuello, E.; Altes, A.; Menoyo, A.; del Rio, E.; Gomez-Pardo, M.; Baiget, M. UGT1A1 gene variations and irinotecan treatment in patients with metasatatic colorectal cancer. Br. J. Cancer 91:678-682; 2004. (Pubitemid 39141623)
10. Carlini, L. E.; Meropol, N. J.; Bever, J.; Andria, M. L.; Hill, T.; Gold, P.; Rogatko, A.; Wang, H.; Blanchard, R. L. UGTIA7 and UGT1A9 polymorphism predict response and toxicity in colorectal cancer patient treated with capecitabine/irinotecan. Clin. Cancer Res. 11:1226-1236; 2005.
11. Font, A.; Sánchez, J. M.; Tarón, M.; Martinez-Balibrea, E.; Sanchez, J. J.; Manzano, J. L.; Margeli, M.; Richardet, M.; Barnadas, A.; Abad, A.; Rosell, R. Weekly regimen of iriontecan/docetaxcel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism. Invest. New Drugs 21:435-443; 2003. (Pubitemid 38124983)
12. Ohe, Y.; Ohashi, Y.; Kubota, K.; Tamura, T.; Nakagawa, K.; Negoro, S.; Nishiwaki, Y.; Saijo, N.; Ariyoshi, Y.; Fukuoka, M. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small cell lung cancer: Four-arm cooperative study in Japan. Ann. Oncol. 18:317-323; 2007.
13. Noda, K.; Nishiwaki, Y.; Kawahara, M.; Negoro, S.; Sugiura, T.; Yokoyama, A.; Fukuoka, M.; Mori, K.; Watanabe, K.; Tamura, T.; Yamamoto, S.; Saijo, N. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med. 346:85-91; 2002.
14. Stewart, C.; Panetta, J. C.; O'Shaughnessy, M. A.; Throm, S. L.; Fraga, C. H.; Owens, T.; Liu, T.; Billups, C.; Rodriguez-Galindo, C.; Gajjar, A.; Furman, W. L.; McGregor, L. M. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. J. Clin. Oncol. 25:2594-2600; 2007.
15. Olivier, M. The invader assay for SNP genotyping. Mutat. Res. 573:103-110; 2005.
16. Minami, H.; Sai, K.; Saeki, M.; Saito, Y.; Ozawa, S.; Suzuki, K.; Kaniwa, N.; Sawada, J.; Hamaguchi, T.; Yamamoto, N.; Shirao, K.; Yamada, Y.; Ohmatsu, H.; Kubota, K.; Yoshida, T.; Ohtsu, A.; Saijo, N. Irinotecan pharmacokinetics/ pharmacodynamics and UGT1A genetic polymorphisms in Japanese: Roles of UGT1A1*6 and *28. Pharmacogenet. Genomics 17:497-504; 2007. (Pubitemid 46905216)
17. Hoskins, J. M.; Goldberg, R. M.; Qu, P.; Ibrahim, J. G.; McLeod, H. UGT1A1*28 genotype and irinotecan-induced neutropenia: Dose matters. J. Natl. Cancer. Inst. 99:1290-1295; 2007.
18. Sai, K.; Saeki, M.; Saito, Y.; Ozawa, S.; Katori, N.; Jinno, H.; Hasegawa, R.; Kaniwa, N.; Sawada, J.; Komamura, K.; Ueno, K.; Kamakura, S.; Kitakaze, M.; Kitamura, Y.; Kamatani, N.; Minami, H.; Ohtsu, A.; Shirao, K.; Yoshida, T.; Saijo, N. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin. Pharmacol. Ther. 75:501-515; 2004.
19. Han, J. Y.; Lim, H. S.; Shin, E. S.; Yoo, Y. K.; Park, Y. H.; Lee, J. E.; Jang, I. J.; Lee, D. H.; Lee, J. S. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J. Clin. Oncol. 24:2237-2244; 2006.
20. Kuehl, P.; Zhang, J.; Lin, Y.; Lamba, J.; Assem, M.; Shuetz, J.; Watkins, P. B.; Daly, A.; Wrighton, S. A.; Hall, S. D.; Maurel, P.; Relling, M.; Brimer, C.; Yasuda, K.; Venkataramanan, R.; Strom, S.; Thummel, K.; Boguski, M. S.; Schuetz, E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27:383-391; 2001.
21. Hoffmeyer, S.; Burk, O.; von Richter, O.; Arnold, H. P.; Brockmoller, J.; Johne, A.; Cascorbi, I.; Gerloff, T.; Roots, I.; Eichelbaum, M.; Brinkmann, U. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 97:3473-3478; 2000.